Arterial stiffness progression in metabolic dysfunction-associated fatty liver disease subtypes: A prospective cohort study

被引:1
|
作者
Liu, Lei [1 ]
Zhou, Yufu
Deng, Shuwen [1 ]
Yuan, Ting [1 ]
Yang, Saiqi [1 ]
Zhu, Xiaoling [1 ]
Wang, Changfa [2 ]
Wang, Yaqin [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Hlth Management Ctr, Dept Gastroenterol, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp 3, Gen Surg Dept, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
关键词
Arterial stiffness; Brachial ankle pulse wave velocity (baPWV); Metabolic dysfunction-associated fatty liver (MAFLD); Diabetes; ASIA-PACIFIC REGION; CARDIOVASCULAR-DISEASE; RISK-FACTORS;
D O I
10.1016/j.numecd.2024.03.030
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: We aimed to investigate the correlation and to explore which MAFLD subtypes have the greatest influence on progression of arterial stiffness risk. Methods and results: Using data from a health examination-based cohort, a total of 12,129 participants who underwent two repeated health examinations that included brachial-ankle pulse wave velocity (baPWV) from 2012 to 2020 were enrolled. Participants were separated into non-MAFLD, overweight/obese (OW-MAFLD), lean/normal weight (lean-MAFLD) and diabetes (DM-MAFLD) groups. Among the participants with a median follow-up of 2.17 years, 4511 (37.2%) participants had MAFLD at baseline, among which 3954 (87.7%), 123 (2.7%), and 434 (9.6%) were OW-, lean- and DM-MAFLD, respectively. Analyses using linear regression models confirmed that compared with the non-MAFLD group, the elevated baPWV change rates (cm/s/ year) were 12.87 (8.81-16.94), 25.33 (7.84-42.83) and 38.49 (27.88-49.10) in OW, lean and DM -MAFLD, respectively, while the increased change proportions (%) were 1.53 (1.10-1.95), 3.56 (1.72-5.40) and 3.94 (2.82-5.05), respectively. Similar patterns were observed when these two baPWV parameters were transformed in the form of the greatest increase using Cox proportional hazards model analyses. Furthermore, the risk of arterial stiffness progression across MAFLD subtypes presented a significant, gradient, inverse relationship in the order of DM-, lean-, OW with metabolic abnormalities (MA)-, and OW without MA-MAFLD. Conclusion: MAFLD, especially DM-MAFLD and lean-MAFLD, was significantly associated with arterial stiffness progression, providing evidence that stratification screening and surveillance strategies for CVD risk have important clinical implications. (c) 2024 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1890 / 1900
页数:11
相关论文
共 50 条
  • [1] Dietary patterns in the progression of metabolic dysfunction-associated fatty liver disease to advanced liver disease: a prospective cohort study
    Li, Tengfei
    Zhao, Jianhui
    Cao, Haoze
    Han, Xin
    Lu, Ying
    Jiang, Fangyuan
    Li, Xinxuan
    Sun, Jing
    Zhou, Siyun
    Sun, Zhongquan
    Wang, Weilin
    Ding, Yuan
    Li, Xue
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2024, 120 (03): : 518 - 527
  • [2] Transition patterns of metabolic dysfunction-associated fatty liver disease status in relation to arterial stiffness progression: a health check-up cohort study
    Liu, Lei
    Wang, Changfa
    Deng, Shuwen
    Yuan, Ting
    Zhu, Xiaoling
    Deng, Yuling
    Qin, Yuexiang
    Wang, Yaqin
    Yang, Pingting
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [3] Transition patterns of metabolic dysfunction-associated fatty liver disease status in relation to arterial stiffness progression: a health check-up cohort study
    Lei Liu
    Changfa Wang
    Shuwen Deng
    Ting Yuan
    Xiaoling Zhu
    Yuling Deng
    Yuexiang Qin
    Yaqin Wang
    Pingting Yang
    Scientific Reports, 13
  • [4] Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang
    Guo, Yanbo
    Yang, Jing
    Ma, Rulin
    Zhang, Xianghui
    Guo, Heng
    He, Jia
    Wang, Xinping
    Cao, Boyu
    Maimaitijiang, Remina
    Li, Yu
    Peng, Xinyu
    Zhang, Shijie
    Guo, Shuxia
    NUTRIENTS, 2022, 14 (12)
  • [5] Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study
    Wang, Xiaomo
    Wu, Shouling
    Yuan, Xiaojie
    Chen, Shuohua
    Fu, Qingjiang
    Sun, Yuanyuan
    Lan, Yanqi
    Hu, Shiqi
    Wang, Yanhong
    Lu, Ying
    Qu, Shunxi
    Wang, Li
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (02): : E745 - E755
  • [6] Healthy Lifestyle and the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Large Prospective Cohort Study
    Chang, Qing
    Zhang, Yixiao
    Zhang, Tingjing
    Liu, Zuyun
    Cao, Limin
    Zhang, Qing
    Liu, Li
    Sun, Shaomei
    Wang, Xing
    Zhou, Ming
    Jia, Qiyu
    Song, Kun
    Ding, Yang
    Zhao, Yuhong
    Niu, Kaijun
    Xia, Yang
    DIABETES & METABOLISM JOURNAL, 2024, 48 (05)
  • [7] Fasting serum fructose is associated with metabolic dysfunction-associated fatty liver disease: A prospective study
    Fan, Yujuan
    Zhang, Yuecheng
    Chen, Congling
    Ying, Zhen
    Su, Qing
    Li, Xiaoying
    Chen, Ying
    HEPATOLOGY RESEARCH, 2023, 53 (06) : 479 - 488
  • [8] Extrahepatic malignancies in metabolic dysfunction-associated fatty liver disease: A nationwide cohort study
    Park, Min Kyung
    Hur, Moon Haeng
    Moon, Hye-Sung
    Shin, Hyunjae
    Chung, Sung Won
    Won, Sungho
    Lee, Yun Bin
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Yu, Su Jong
    Yoon, Jung-Hwan
    Kim, Yoon Jun
    LIVER INTERNATIONAL, 2024, 44 (03) : 799 - 810
  • [9] Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study
    van Kleef, Laurens A.
    Ayada, Ibrahim
    Alferink, Louise J. M.
    Pan, Qiuwei
    Knegt, Robert J.
    HEPATOLOGY, 2022, 75 (02) : 419 - 429
  • [10] Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study
    Chen, Jie
    Dan, Lintao
    Tu, Xinru
    Sun, Yuhao
    Deng, Minzi
    Chen, Xuejie
    Hesketh, Therese
    Li, Ran
    Wang, Xiaoyan
    Li, Xue
    HEPATOLOGY INTERNATIONAL, 2023, 17 (01) : 202 - 214